Glycosylation Modulates Plasma Membrane Trafficking of CD24 in Breast Cancer Cells.
CD24
breast cancer
endocytic sorting
glycosylation
luminal and basal B cell lines
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
29 Jul 2021
29 Jul 2021
Historique:
received:
09
07
2021
revised:
27
07
2021
accepted:
27
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
14
9
2021
Statut:
epublish
Résumé
In breast cancer, expression of Cluster of Differentiation 24 (CD24), a small GPI-anchored glycoprotein at the cell periphery, is associated with metastasis and immune escape, while its absence is associated with tumor-initiating capacity. Since the mechanism of CD24 sorting is unknown, we investigated the role of glycosylation in the subcellular localization of CD24. Expression and localization of wild type N36- and/or N52-mutated CD24 were analyzed using immunofluorescence in luminal (MCF-7) and basal B (MDA-MB-231 and Hs578T) breast cancer cells lines, as well as HEK293T cells. Endogenous and exogenously expressed wild type and mutated CD24 were found localized at the plasma membrane and the cytoplasm, but not the nucleoplasm. The cell lines showed different kinetics for the sorting of CD24 through the secretory/endocytic pathway. N-glycosylation, especially at N52, and its processing in the Golgi were critical for the sorting and expression of CD24 at the plasma membrane of HEK293T and basal B type cells, but not of MCF-7 cells. In conclusion, our study highlights the contribution of N-glycosylation for the subcellular localization of CD24. Aberrant N-glycosylation at N52 of CD24 could account for the lack of CD24 expression at the cell surface of basal B breast cancer cells.
Identifiants
pubmed: 34360932
pii: ijms22158165
doi: 10.3390/ijms22158165
pmc: PMC8347636
pii:
doi:
Substances chimiques
CD24 Antigen
0
CD24 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Special Account for Research Funds of the University of Crete
ID : KA10398
Références
Mol Syst Biol. 2018 Nov 20;14(11):e8486
pubmed: 30459171
Nat Commun. 2015 Jan 20;6:5909
pubmed: 25600590
Science. 2004 Oct 1;306(5693):120-4
pubmed: 15459394
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Cancer Lett. 2010 Feb 1;288(1):99-106
pubmed: 19619935
Mol Pharmacol. 2005 Mar;67(3):868-76
pubmed: 15576633
Biochem J. 1997 Nov 1;327 ( Pt 3):759-64
pubmed: 9581553
PLoS One. 2014 Jun 23;9(6):e99412
pubmed: 24955581
Cancer Res. 2017 Sep 15;77(18):4858-4867
pubmed: 28674079
N Engl J Med. 2009 Feb 19;360(8):790-800
pubmed: 19228622
Cancer Res. 2011 Feb 1;71(3):895-905
pubmed: 21266361
Biochim Biophys Acta. 2013 Nov;1833(11):2430-7
pubmed: 23583305
Anticancer Res. 2016 Dec;36(12):6593-6598
pubmed: 27919988
BMC Res Notes. 2013 Aug 12;6:317
pubmed: 23937900
J Lipid Res. 2016 Jan;57(1):4-5
pubmed: 26582962
J Cell Biol. 2004 Nov 22;167(4):699-709
pubmed: 15557121
Cell Oncol (Dordr). 2019 Apr;42(2):237-242
pubmed: 30680705
Br J Cancer. 2018 Mar 20;118(6):847-856
pubmed: 29381688
J Lipid Res. 2008 Jun;49(6):1312-21
pubmed: 18340083
J Nutr. 2004 Feb;134(2):308-16
pubmed: 14747665
J Transl Med. 2016 Feb 01;14:32
pubmed: 26830684
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
pubmed: 12629218
Clin Cancer Res. 2005 Sep 15;11(18):6574-81
pubmed: 16166435
Cell Mol Immunol. 2010 Mar;7(2):100-3
pubmed: 20154703
Am J Physiol Heart Circ Physiol. 2002 Jul;283(1):H77-84
pubmed: 12063277
Nature. 2019 Aug;572(7769):392-396
pubmed: 31367043
Int J Biol Markers. 2017 May 4;32(2):e182-e189
pubmed: 28315505
Am J Biomed Sci. 2009 Jan 1;1(1):1-11
pubmed: 20407596
Breast Cancer Res. 2020 Jun 9;22(1):61
pubmed: 32517735
Oncogene. 2010 May 6;29(18):2672-80
pubmed: 20190812
Int J Cell Biol. 2015;2015:505294
pubmed: 26351455
Am J Physiol Cell Physiol. 2006 Jan;290(1):C1-C10
pubmed: 16338974
Front Oncol. 2020 Jul 29;10:1218
pubmed: 32850359
J Biol Chem. 2001 Apr 13;276(15):11956-62
pubmed: 11134020
Am J Clin Pathol. 2015 Oct;144(4):642-8
pubmed: 26386086
Mol Cell Proteomics. 2015 Aug;14(8):2103-10
pubmed: 25995273
Nucleic Acids Res. 2004 Aug 10;32(14):e115
pubmed: 15304544
FASEB J. 1998 Sep;12(12):1241-51
pubmed: 9737727
Clin Breast Cancer. 2009 Jun;9 Suppl 2:S73-81
pubmed: 19596646
Mol Oncol. 2015 Apr;9(4):861-76
pubmed: 25655580
Cancer Res. 2005 Dec 1;65(23):10783-93
pubmed: 16322224
Nat Commun. 2016 Aug 30;7:12632
pubmed: 27572267
Int J Cancer. 2021 Feb 1;148(3):546-559
pubmed: 32790899
Lab Invest. 2010 Jul;90(7):1102-16
pubmed: 20351695
Crit Rev Biochem Mol Biol. 1998;33(3):151-208
pubmed: 9673446
Cancer Res. 2005 Aug 15;65(16):7455-61
pubmed: 16103099
Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3722-7
pubmed: 20133591
Viruses. 2016 Feb 29;8(3):62
pubmed: 26938549
Br J Cancer. 2008 Feb 26;98(4):756-65
pubmed: 18268494
J Cell Sci. 2019 Oct 23;132(20):
pubmed: 31455607
J Clin Pathol. 2011 Nov;64(11):937-46
pubmed: 21680574
J Clin Oncol. 2005 Oct 10;23(29):7350-60
pubmed: 16145060
J Biol Chem. 2012 May 11;287(20):16399-409
pubmed: 22431723
Nat Rev Mol Cell Biol. 2012 Jun 22;13(7):448-62
pubmed: 22722607
Curr Cancer Drug Targets. 2018;18(4):328-336
pubmed: 28820056
J Proteome Res. 2012 Feb 3;11(2):656-67
pubmed: 22106898
FEBS J. 2010 Aug;277(15):3219-34
pubmed: 20618438
Biochimie. 2003 Jun;85(6):565-73
pubmed: 12829373
Breast Cancer Res. 2021 Jun 13;23(1):66
pubmed: 34120626